Recent Quotes

My Watchlist

Indicators

Currencies

International

Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

1.150 +0.090 (+8.49%)

Streaming Delayed Price Updated: 9:38 AM EDT, Mar 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	11,955,223
Open	1.140
Bid (Size)	1.140 (1,300)
Ask (Size)	1.150 (1,900)
Prev. Close	1.060
Today's Range	1.090 - 1.160
52wk Range	0.6930 - 46.53
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

Today 7:47 EDT

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

March 03, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

Performance

YTD	-5.7%	-5.7%
1 Month	+27.8%	+27.8%
3 Month	-30.3%	-30.3%
6 Month	-84.4%	-84.4%
1 Year	-89.4%	-89.4%

More News

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

February 25, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer

February 19, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study

February 17, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

February 09, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

January 07, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

December 03, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

November 14, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

November 05, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

October 28, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

October 20, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains? ↗

October 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 16, 2025

Via Benzinga

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

October 16, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

October 15, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

October 09, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

October 08, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

These stocks that are showing activity before the opening bell on Wednesday. ↗

October 08, 2025

Via Chartmill

What's Driving bioAffinity Technologies' Big Pre-Market Surge? ↗

October 08, 2025

Via Benzinga

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

October 07, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

September 30, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Energy Fuels, Firefly Aerospace And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 30, 2025

Via Benzinga

Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket ↗

September 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 29, 2025

Via Benzinga

Frequently Asked Questions

Is bioAffinity Technologies, Inc. - Common Stock publicly traded?

Yes, bioAffinity Technologies, Inc. - Common Stock is publicly traded.

What exchange does bioAffinity Technologies, Inc. - Common Stock trade on?

bioAffinity Technologies, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for bioAffinity Technologies, Inc. - Common Stock?

The ticker symbol for bioAffinity Technologies, Inc. - Common Stock is BIAF on the Nasdaq Stock Market

What is the current price of bioAffinity Technologies, Inc. - Common Stock?

The current price of bioAffinity Technologies, Inc. - Common Stock is 1.150

When was bioAffinity Technologies, Inc. - Common Stock last traded?

The last trade of bioAffinity Technologies, Inc. - Common Stock was at 03/10/26 09:38 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.